Table 2.
Application of bevacizumab (BVZ) in patients with (infant) chiasmatic hypothalamic glioma (n = number of respondents)
| n | % | |
|---|---|---|
| Experience with BVZ in CHG | ||
| Yes | 25 | 53 |
| No | 22 | 47 |
| Experience of BVZ in CHG patients per respondent | ||
| None | 22 | 47 |
| 1 | 3 | 6 |
| 2–5 | 16 | 34 |
| 6–10 | 2 | 4 |
| 11–15 | 3 | 6 |
| > 15 | 1 | 2 |
| % of CHG patients with stable disease or regression (n = number of respondents, not patients treated!) | ||
| 0–20% | 1 | 4 |
| 20–40% | 4 | 16 |
| 40–60% | 5 | 20 |
| > 60% | 15 | 60 |
| Not applicable | 22 | |
| Patients with CHG treated with BVZ below 1 year of age | ||
| None | 30 | 64 |
| 1 | 11 | 23 |
| 2–5 | 5 | 11 |
| 6–10 | – | |
| 11–15 | – | |
| > 15 | – | |
| Missing | 1 | 2 |
| Duration of bevacizumab treatment (in months) | ||
| Not available | 25 | |
| 0–3 | – | |
| 4–6 | 3 | |
| 7–9 | 3 | |
| 10–12 | 11 | |
| 13–18 | 1 | |
| 19–24 | 4 | |
| > 24 | – | |
| Major complications | ||
| Yes | 3 | 12 |
| No | 22 | 88 |
| Type of complications | ||
| Intracranial bleeding | 0 | |
| Bleeding outside of CNS | 1 | |
| Hypertension | 1 | |
| Proteinuria | 1 | |
| Wound healing problems | 0 | |
| Other | 0 | |
| Combination of BVZ with other drugs | ||
| Yes | 23 | 92 |
| No | 2 | 8 |
| Drugs applied together with BVZ | ||
| Irinotecan | 20 | |
| Vinblastine | 1 | |
| Thalidomide | 1 | |
| Missing | 1 | |